
Natarajan Vijayasankaran
Advertisement
Natarajan Vijayasankaran is engineer II at late stage cell culture, US Biologics Pharma Technical Development, Genentech, Inc.
Articles by Natarajan Vijayasankaran

Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Alvotech, Advanz Submit First Eylea 8 mg Biosimilar Bid
2
FDA Accepts BLA for Formycon and Zydus’ FYB206, the First Publicly Announced Keytruda Biosimilar Under Review
3
Lilly's Mirikizumab (Omvoh) Hits New IBD Remission Goals
4
FDA Expands Anktiva Approval to Papillary-Only BCG-Unresponsive Bladder Cancer
5


